Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement

Meinrad Gawaz, Andreas Ruf, Franz Josef Neumann, Gisela Pogátsa-Murray, Timm Dickfeld, Dietlind Zohlnhöfer, Albert Schömig

Research output: Contribution to journalArticle

Abstract

Platelet membrane glycoproteins play a crucial role in ischemic complications after coronary stenting. Glycoprotein IIb-IIIa blockade reduces adverse clinical events after angioplasty but is associated with rare but profound thrombocytopenia that might increase hemorrhagic complications. Changes in platelet membrane glycoproteins of patients with angina who underwent coronary stenting and were treated with the GPIIb-IIIa antagonist abciximab (n = 20) or with heparin (n = 23) were studied. GPIIb-IIIa receptor blockade and membrane glycoproteins were evaluated with immunological markers in venous blood samples taken before, 10, 24, 48, 72, and 96 h after initial treatment with either abciximab or heparin. Patients receiving abciximab therapy showed a rapid inhibition of binding of fluorochrome-conjugated mAb CD41 and c7E3 concomitant with a reduction in platelet aggregation which was restored in part in the days after termination of abciximab infusion. Induction of ligand-induced binding sites on GPIIb-IIIa was increased in patients receiving abciximab. The expression of ligand-induced binding sites correlated inversely with platelet count. No significant change in platelet membrane markers were found in the heparin group. In vitro studies showed that abciximab induces ligand-induced binding sites on isolated platelets and on nuclear cells bearing recombinant GPIIb-IIIa. Abciximab rapidly achieves GPIIb-IIIa receptor blockade after coronary stent placement that might be beneficial in high-risk settings to bridge the delayed action of ticlopidine. Significant alterations of platelet membrane glycoproteins during GPIIb-IIIa antagonism might contribute to development of acute profound thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)994-1001
Number of pages8
JournalThrombosis and Haemostasis
Volume80
Issue number6
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Platelet Membrane Glycoproteins
Platelet Glycoprotein GPIIb-IIIa Complex
Stents
Heparin
Binding Sites
Ligands
Thrombocytopenia
Blood Platelets
Ticlopidine
Membrane Glycoproteins
abciximab
Platelet Count
Platelet Aggregation
Fluorescent Dyes
Angioplasty
Membranes
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Gawaz, M., Ruf, A., Neumann, F. J., Pogátsa-Murray, G., Dickfeld, T., Zohlnhöfer, D., & Schömig, A. (1998). Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thrombosis and Haemostasis, 80(6), 994-1001.

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. / Gawaz, Meinrad; Ruf, Andreas; Neumann, Franz Josef; Pogátsa-Murray, Gisela; Dickfeld, Timm; Zohlnhöfer, Dietlind; Schömig, Albert.

In: Thrombosis and Haemostasis, Vol. 80, No. 6, 12.1998, p. 994-1001.

Research output: Contribution to journalArticle

Gawaz, M, Ruf, A, Neumann, FJ, Pogátsa-Murray, G, Dickfeld, T, Zohlnhöfer, D & Schömig, A 1998, 'Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement', Thrombosis and Haemostasis, vol. 80, no. 6, pp. 994-1001.
Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thrombosis and Haemostasis. 1998 Dec;80(6):994-1001.
Gawaz, Meinrad ; Ruf, Andreas ; Neumann, Franz Josef ; Pogátsa-Murray, Gisela ; Dickfeld, Timm ; Zohlnhöfer, Dietlind ; Schömig, Albert. / Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. In: Thrombosis and Haemostasis. 1998 ; Vol. 80, No. 6. pp. 994-1001.
@article{01033ebaab8b48c2b2f6b07823712108,
title = "Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement",
abstract = "Platelet membrane glycoproteins play a crucial role in ischemic complications after coronary stenting. Glycoprotein IIb-IIIa blockade reduces adverse clinical events after angioplasty but is associated with rare but profound thrombocytopenia that might increase hemorrhagic complications. Changes in platelet membrane glycoproteins of patients with angina who underwent coronary stenting and were treated with the GPIIb-IIIa antagonist abciximab (n = 20) or with heparin (n = 23) were studied. GPIIb-IIIa receptor blockade and membrane glycoproteins were evaluated with immunological markers in venous blood samples taken before, 10, 24, 48, 72, and 96 h after initial treatment with either abciximab or heparin. Patients receiving abciximab therapy showed a rapid inhibition of binding of fluorochrome-conjugated mAb CD41 and c7E3 concomitant with a reduction in platelet aggregation which was restored in part in the days after termination of abciximab infusion. Induction of ligand-induced binding sites on GPIIb-IIIa was increased in patients receiving abciximab. The expression of ligand-induced binding sites correlated inversely with platelet count. No significant change in platelet membrane markers were found in the heparin group. In vitro studies showed that abciximab induces ligand-induced binding sites on isolated platelets and on nuclear cells bearing recombinant GPIIb-IIIa. Abciximab rapidly achieves GPIIb-IIIa receptor blockade after coronary stent placement that might be beneficial in high-risk settings to bridge the delayed action of ticlopidine. Significant alterations of platelet membrane glycoproteins during GPIIb-IIIa antagonism might contribute to development of acute profound thrombocytopenia.",
author = "Meinrad Gawaz and Andreas Ruf and Neumann, {Franz Josef} and Gisela Pog{\'a}tsa-Murray and Timm Dickfeld and Dietlind Zohlnh{\"o}fer and Albert Sch{\"o}mig",
year = "1998",
month = "12",
language = "English (US)",
volume = "80",
pages = "994--1001",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement

AU - Gawaz, Meinrad

AU - Ruf, Andreas

AU - Neumann, Franz Josef

AU - Pogátsa-Murray, Gisela

AU - Dickfeld, Timm

AU - Zohlnhöfer, Dietlind

AU - Schömig, Albert

PY - 1998/12

Y1 - 1998/12

N2 - Platelet membrane glycoproteins play a crucial role in ischemic complications after coronary stenting. Glycoprotein IIb-IIIa blockade reduces adverse clinical events after angioplasty but is associated with rare but profound thrombocytopenia that might increase hemorrhagic complications. Changes in platelet membrane glycoproteins of patients with angina who underwent coronary stenting and were treated with the GPIIb-IIIa antagonist abciximab (n = 20) or with heparin (n = 23) were studied. GPIIb-IIIa receptor blockade and membrane glycoproteins were evaluated with immunological markers in venous blood samples taken before, 10, 24, 48, 72, and 96 h after initial treatment with either abciximab or heparin. Patients receiving abciximab therapy showed a rapid inhibition of binding of fluorochrome-conjugated mAb CD41 and c7E3 concomitant with a reduction in platelet aggregation which was restored in part in the days after termination of abciximab infusion. Induction of ligand-induced binding sites on GPIIb-IIIa was increased in patients receiving abciximab. The expression of ligand-induced binding sites correlated inversely with platelet count. No significant change in platelet membrane markers were found in the heparin group. In vitro studies showed that abciximab induces ligand-induced binding sites on isolated platelets and on nuclear cells bearing recombinant GPIIb-IIIa. Abciximab rapidly achieves GPIIb-IIIa receptor blockade after coronary stent placement that might be beneficial in high-risk settings to bridge the delayed action of ticlopidine. Significant alterations of platelet membrane glycoproteins during GPIIb-IIIa antagonism might contribute to development of acute profound thrombocytopenia.

AB - Platelet membrane glycoproteins play a crucial role in ischemic complications after coronary stenting. Glycoprotein IIb-IIIa blockade reduces adverse clinical events after angioplasty but is associated with rare but profound thrombocytopenia that might increase hemorrhagic complications. Changes in platelet membrane glycoproteins of patients with angina who underwent coronary stenting and were treated with the GPIIb-IIIa antagonist abciximab (n = 20) or with heparin (n = 23) were studied. GPIIb-IIIa receptor blockade and membrane glycoproteins were evaluated with immunological markers in venous blood samples taken before, 10, 24, 48, 72, and 96 h after initial treatment with either abciximab or heparin. Patients receiving abciximab therapy showed a rapid inhibition of binding of fluorochrome-conjugated mAb CD41 and c7E3 concomitant with a reduction in platelet aggregation which was restored in part in the days after termination of abciximab infusion. Induction of ligand-induced binding sites on GPIIb-IIIa was increased in patients receiving abciximab. The expression of ligand-induced binding sites correlated inversely with platelet count. No significant change in platelet membrane markers were found in the heparin group. In vitro studies showed that abciximab induces ligand-induced binding sites on isolated platelets and on nuclear cells bearing recombinant GPIIb-IIIa. Abciximab rapidly achieves GPIIb-IIIa receptor blockade after coronary stent placement that might be beneficial in high-risk settings to bridge the delayed action of ticlopidine. Significant alterations of platelet membrane glycoproteins during GPIIb-IIIa antagonism might contribute to development of acute profound thrombocytopenia.

UR - http://www.scopus.com/inward/record.url?scp=0031732864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031732864&partnerID=8YFLogxK

M3 - Article

C2 - 9869173

AN - SCOPUS:0031732864

VL - 80

SP - 994

EP - 1001

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -